{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-084737","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.465073+00:00","generated_at":"2026-05-17T08:05:33.452622+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CERo Therapeutics receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia","bullets":["FDA granted Fast Track Designation for CER-1236 in AML, adding to existing Orphan Drug Designation.","Benefits include increased FDA interactions, potential priority review, rolling submission, and expanded access.","Phase 1/1b study underway evaluating CER-1236 in relapsed/refractory AML, MRD-positive, or TP53-mutated MDS/AML.","CEO Chris Ehrlich noted the designation validates program urgency and may accelerate development and market timeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-084737","json":"https://secwatch.observer/filing/0001213900-25-084737.json","markdown":"https://secwatch.observer/filing/0001213900-25-084737.md","text":"https://secwatch.observer/filing/0001213900-25-084737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025084737/0001213900-25-084737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025084737/ea0256155-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:05:33.452622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}